

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Masayuki AMAGAI and Takeji NISHIKAWA
Group Art Unit: TBA
Serial No.: 10/510,001
Filed: September 30, 2004 Examiner: TBA
International Application No.: PCT/JP03/04219 International Filing Date: April 2, 2003
For: REMEDIES FOR PEMPHIGUS CONTAINING CD40L ANTAGONIST
AS THE ACTIVE INGREDIENT

STATEMENT UNDER 37 C.F.R. §1.821 or §1.825


Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that:

- ☐ [] The Sequence Listing information recorded in computer-readable form is identical to the written form of the Sequence Listing on paper or compact disc (37 C.F.R. §1.821(f)), and the submission does not include new matter (37 C.F.R. §1.821(g)).
- ☒ [X] The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted,


Evelyn M. Kwon
Registration No. 54,246

Date: August 3, 2005

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, New York 10281
Tel. No. (212) 415-8700
Fax No. (212) 415-8701